NSE · VINEETLAB · Basic Materials
Vineet Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹77 Cr with net profit ₹-20 Cr — a -26.23% net margin, versus 0.68% the period before.
Shareholding
As of 2026-06-30
- Promoter5.98%
- Public93.52%
- FII0.5%
9,901 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.79× from low to high.
Risk flags
Derived from disclosed data
- Reported zero revenue in 2 of the last 7 disclosed periods.
Peer comparison
Chemicals · ranked #123 of 161 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Solar Industries India Ltd. | ₹1,79,985 Cr | 90.38 | 28.81 | 26.72% | 17.54% |
| Pidilite Industries Ltd. | ₹1,60,186 Cr | 60.49 | 14.77 | 22.61% | 17.2% |
| SRF Ltd. | ₹75,242 Cr | 33.58 | 5.35 | 13.07% | 13.01% |
| Linde India Limited | ₹53,900 Cr | 98.64 | 12.61 | 12.87% | 20.59% |
| Gujarat Fluorochemicals Ltd. | ₹49,292 Cr | 79.8 | 6.31 | 7.13% | 11.41% |
| Navin Fluorine International Ltd. | ₹43,299 Cr | 54.45 | 10.89 | 16.69% | 21.73% |
| Godrej Industries Ltd. | ₹37,040 Cr | 30.28 | 3.31 | 11.1% | 5.06% |
| Himadri Speciality Chem Limited | ₹33,779 Cr | 42.26 | 7.17 | 15.96% | 16.07% |
| Deepak Nitrite Ltd. | ₹22,003 Cr | 27.78 | 3.77 | 9.43% | 9.13% |
| Aether Industries Limited | ₹21,814 Cr | 90.9 | 8.88 | 8.94% | 19.11% |
| Vineet Laboratories Ltd.(this company) | ₹67 Cr | 60.02 | 1.45 | 2.44% | 1.87% |
AI analysis
AI-generated · google/gemini-2.5-flashVineet Laboratories Ltd. has a market capitalization of Rs 72 Cr. The company reported revenue of Rs 76.98 Cr in the latest fiscal year. Its book value is Rs 15.89. The company's EPS is -21.9 and it has a negative ROCE of -22.411%.
Positives
- +The promoter pledge is 0%, indicating no shares are pledged.
- +FII holding has a presence at 0.36% as of March 2026.
Negatives
- −The company reported a negative EPS of -21.9 in Mar 2025.
- −Revenue has significantly declined to Rs 76.98 Cr in Mar 2025 from Rs 243.86 Cr in Mar 2021.
- −The company reported a net loss of Rs -20.19 Cr in Mar 2025.
- −Return on Capital Employed (ROCE) is negative at -22.411%.
- −Promoter holding has decreased substantially from 38.66% in Mar 2023 to 5.98% in Mar 2026.
- −The debt-to-equity ratio is high at 1.71.
Financial performance
Vineet Laboratories Ltd. has experienced a decline in revenue over recent years. Revenue decreased from Rs 243.86 Cr in Mar 2021 to Rs 76.98 Cr in Mar 2025. Net profit also saw a significant drop, falling from Rs 1.78 Cr in Mar 2021 to a net loss of Rs -20.19 Cr in Mar 2025. The company's latest annual EBITDA was -16.79 Cr in Mar 2025.
Profitability & returns
The company's profitability has deteriorated, with a negative EPS of -21.9 in Mar 2025, down from 1.11 in Mar 2024. Return on Capital Employed (ROCE) is significantly negative at -22.411%. Return on Equity (ROE) is 0%, reflecting no returns for equity shareholders. The net profit has moved from positive to negative, reporting a loss of Rs -20.19 Cr in Mar 2025.
Balance sheet
Vineet Laboratories Ltd. has a debt-to-equity ratio of 1.71, indicating a reliance on debt financing. The book value per share is Rs 15.89. The company's EBITDA for Mar 2025 was -16.79 Cr, while its net profit was -20.19 Cr in the same period.
Ownership & pledges
Public shareholding is dominant at 93.66%. There are no shares pledged by the promoters.
Data as of — price: 2026-09-23 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.